PDF(Pubmed)
Abstract：
Numerous biomarkers that reflect host status have been identified for patients with metastatic colorectal cancer (mCRC). However, there has been a paucity of biomarker studies that comprehensively indicate body composition, nutritional assessment, and systemic inflammation status. The advanced lung cancer inflammation index (ALI), initially introduced as a screening tool for patients with non-small-cell lung cancer in 2013, emerges as a holistic marker encompassing all body composition, nutritional status, and systemic inflammation status. The index is calculated by the simple formula: body mass index × albumin value / neutrophil-to-lymphocyte ratio. Given its accessibility in routine clinical practice, the ALI has exhibited promising clinical utility in prognosticating outcomes for patients with multiple types of cancer. In this review, we focus on the significance of host status and the clinical applicability of the ALI in the treatment and management of patients with malignancies, including mCRC. We also suggest its potential in guiding the formulation of treatment strategies against mCRC and outline future perspectives.
摘要：
已经为转移性结直肠癌（mCRC）患者鉴定了许多反映宿主状态的生物标志物。然而,缺乏全面指示身体成分的生物标志物研究，营养评估,和全身炎症状态。晚期肺癌炎症指数（ALI），最初于2013年作为非小细胞肺癌患者的筛查工具推出，成为涵盖所有身体成分的整体标志物，营养状况,和全身炎症状态。该指数通过简单公式计算：体重指数×白蛋白值/中性粒细胞与淋巴细胞之比。鉴于其在常规临床实践中的可及性，ALI在预测多种类型癌症患者的预后方面显示出有希望的临床应用价值.在这次审查中,我们专注于宿主状态的重要性和ALI在恶性肿瘤患者的治疗和管理中的临床适用性，包括mCRC。我们还提出了其在指导制定针对mCRC的治疗策略方面的潜力，并概述了未来的前景。
